CA 15-3

Референтні значення:

Раковий антиген 15-3 (СА 15-3) використовується для контролю відповіді на лікування раку молочної залози та рецидиву захворювання.

Опорний діапазон сироватки СА 15-3 становить менше 30 ОД / мл. Верхня межа діапазону змінюється залежно від лабораторії та набору, який використовується для тесту. Значення, отримані в різних наборах, методах чи лабораторіях аналізу, не можуть бути взаємозамінними.

ДЖЕРЕЛА:

  1. Swart R. Breast Cancer. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/1947145-overview.
  2. Bon GG et al. Clinical and technical evaluation of ACS™BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clinical Chemistry. 1997. 43(4):585-593.
  3. Wu JT. Expression of monoclonal antibody-defined tumor markers in four carcinomas. Ann Clin Lab Sci. 1989 Jan-Feb. 19(1):17-26. [Medline].
  4. Duffy MJ, Shering S, Sherry F, McDermott E, O’Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers. 2000 Oct-Dec. 15(4):330-3. [Medline].
  5. Klee GG, Schreiber WE. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen?. Arch Pathol Lab Med. 2004 Oct. 128(10):1131-5. [Medline].
  6. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20. 25(33):5287-312. [Medline].
  7. Gheybi E, Amani J, Salmanian AH, Mashayekhi F, Khodi S. Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer. Tumour Biol. 2014 Aug 16. [Medline].
  8. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer. 2002 Apr 22. 86(8):1217-22. [Medline].
  9. Wang G, Qin Y, Zhang J, Zhao J, Liang Y, Zhang Z, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci. 2014 May 28. 15(6):9546-65. [Medline]. [Full Text].
  10. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002 Jun. 38(9):1189-93. [Medline].
  11. Nicolini A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006 Nov. 20(6):269.
  12. Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, et al. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve. Nuklearmedizin. 2014 Aug 6. 53(4):131-8. [Medline].
  13. Cervino AR, Saibene T, Michieletto S, Ghiotto C, Bozza F, Saladini G, et al. Correlation between Cancer Antigen 15.3 Value and Qualitative and Semi-quantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer patients. Curr Radiopharm. 2014 May 15. [Medline].
  14. Nicolini A, Carpi A, Ferrari P, et al. An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag Res. 2018. 10:6879-86. [Medline]. [Full Text].
  15. Lasham A, Fitzgerald SJ, Knowlton N, et al. A Predictor of Early Disease Recurrence in Patients With Breast Cancer Using a Cell-free RNA and Protein Liquid Biopsy. Clin Breast Cancer. 2019 Aug 22. [Medline].
  16. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002 Aug. 48(8):1151-9. [Medline].

Залишити коментар

Ваша e-mail адреса не оприлюднюватиметься. Обов’язкові поля позначені *